Epirubicin HCl toxicity in human liver-derived hepatoma G2 cells

Polish Journal of Pharmacology

Volumn 56, Issue 4, 2004, Pages 435-444

  Ozkan, Aysun ^a   Fişkin, Kayahan ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Catalase; Cytotoxicity; Epirubicin HCl; Glutathione peroxidase; Glutathione reductase; Hepatoma G2 cells; Superoxide dismutase

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; DNA FRAGMENT; DOXORUBICIN DERIVATIVE; EPIRUBICIN; FREE RADICAL; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; SELENIUM; SUPEROXIDE DISMUTASE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; LIPID PEROXIDATION; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPIRUBICIN; HUMANS; INHIBITORY CONCENTRATION 50; REACTIVE OXYGEN SPECIES; TIME FACTORS;

EID: 9744255513     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res, 1978, 38, 1745-1750.
2. Bachur NR, Gee MV, Friedman RD: Nuclear-catalysed antibiotic free radical formation. Cancer Res, 1982, 42, 1078-1081.
3. Begleiter A: Cytocidal action of the quinone group and its relationship to antitumour activity. Cancer Res, 1983, 43, 481-484.
4. Bonadonna G, Monfardini S, Delene MD, Fossati-Bellani F, Bretter G: Phase I and preliminary phase II evaluation of adriamycin (NSC-123127). Cancer Res, 1970, 30, 2572-2582.
5. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein dye binding. Anal Biochem, 1976, 72, 248-254.
6. Buttke TM, Sandstrom PA: Oxidative stress as a mediator of apoptosis. Immunol Today, 1994, 15, 7-10.
7. Carlberg I, Mannervik B: Glutathione reductase. Methods Enzymol, 1985, 11, 3448-3490.
8. Chan TT, Weichmann BM: Pomedalac: a novel and long-acting non-narcotic analgesic. J Pharmacol Exp Ther, 1989, 248, 907-915.
9. Chen Q, Galleano M, Cederbaum I: Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1. J Biol Chem, 1997, 272, 14532-14541.
10. Davies SM, Robson CN, Davies SL, Hickson ID: Nuclear topoisomerse II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem, 1988, 263, 17724-17729.
11. De Vries EGE, Meijer C, Timmer-Bosscha H, Berendsen HH, de Leij L, Scheper RJ, Mulder NH: Resistance mechanism in three human small cell lung cancer cell lines established from one patient during clinical follow up. Cancer Res, 1989, 49, 4175-4178.
12. Dierickx PJ: Glutathione-dependent cytotoxicity of the chloroacetanilide herbicides alachlor, metolachor, and propachlor in rat and human hepatoma-derived cultured cells. Cell Biol Toxicol, 1999, 15, 325-332.
13. Duncan DB: Multiple range and multiple F test. Biometrics, 1955, 11, 111-114.
14. Frusawa S, Nakana S, Wada M, Chiba H, Takayanagi M, Takayanagi Y, Sasaki K: Augmentation of epirubicin HCl cytotoxicity by cycloheximide. Res Commun Mol Pathol Pharmacol, 1996, 91, 245-252.
15. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol, 1992, 119, 493-501.
16. Glisson BS, Ross WE: DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther, 1987, 32, 89-106.
17. Gutteridge JMC, Hallýwel B: The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci, 1990, 15, 129-135.
18. Habig WH, Jakoby WB: Assay for differentiation of glutathione S-transferases. Methods Enzymol, 1981, 77, 398-405.
19. Haniu M, McManus ME, Birkett DJ, Lee TD, Sihively EJ: Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites. Biochemistry, 1989, 28, 8639-8645.
20. Hao XY, Bergh J, Brodin O, Hellman U, Mannervik B: Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis, 1994, 15, 1167-1173.
21. Henriksson R, Grankvist K: Protective effect of iron chelators on epirubicin HCl-induced fibroblast toxicity. Cancer Lett, 1988, 43, 179-183.
22. Iyanagi T, Yamazaki I: One-electron-transfer reactions in biochemical systems. V. Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase). Biochim Biophys Acta, 1970, 216, 282-294.
23. Julicher RH, Sterremberg L, Bast A, Riksen RO, Koomen JM, Nordhoek JL: The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart. J Pharm Pharmacol, 1986, 38, 277-282.
24. Kappus H: Overwiev of enzyme systems involved in bio-reduction of drugs and in redox cycling. Biochem Pharmacol, 1986, 35, 1-6.
25. Kappus H: Oxidative stress in chemical toxicity. Arch Toxicol, 1987, 60, 144-149.
26. Kinnula K, Linnaýnma K, Raývýo KO, Kinnula VL: Endogenous antioxidant enzymes and glutathione S-transferase in protection of mesothelioma cells against hydrogen peroxide and epirubicin toxicity. Br J Cancer, 1998, 77, 1097-1102.
27. Lawrence RA, Burk RF: Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun, 1976, 71, 952-958.
28. Lind C, Hochstein P, Ernster L: DT-diaphorase as a quinone reductase: a cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys, 1982, 216, 178-185.
29. Luck H: Catalase. In: Methods of Enzymatic Analayses. Ed. Bergmeyer HU, Academic Press, Weinheim, New York, 1965, 885-894.
30. Maniatis T, Fritsch EF, Sambrok J: Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory, New York, 1982.
31. McCord JM, Fridovich IJ: Superoxide dismutase an enzymatic function for erythrocuprein (hemocuprein). Biol Chem, 1969, 244, 6049-6055.
32. Montironi R, Mazzucchelli R, Pomante R, Thompson D, Duval da Silva V, Vaught L, Bartels PH: Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride. J Clin Pathol, 1999, 52, 350-354.
33. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 1983, 65, 55-63.
34. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger KR, Young RC: Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumour response. Science, 1997, 197, 165-167.
35. Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H, Muto Y. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun, 1995, 207, 382-388.
36. 2 in vitro and in vivo and reduce menadione-reduced DNA injury and cytotoxicity. Am J Physiol, 1995, 268, C227-C236.
37. O'Connell M, Halliwell B, Moorhouse CP, Aruoma OI, Baum H, Peters TJ: Formation of hydroxyl radicals in the presence of ferritin and haemosiderin. Is a haemosiderin formation a biological protective mechanism? Biochem J, 1986, 234, 727-731.
38. Oldham RK, Pomeroy TC: Treatment of Ewing's sarcoma with adriamycin (NSC-123127). Cancer Chemother Rep, 1972, 56, 635-639.
39. Ozkan A, Fişkin K: Investigation of effects of epirubicin HCl and LAK on antioxidant mechanism and free radicals scavenger enzymes in hepatoma G2 cell line. Akdeniz University, Doctor's thesis, 2002.
40. Ozkan A, Fişkin K: epirubicin HCl cytotoxicity in non-small cell lung cancer (NSCLC) cells. Turk J Oncol Hematol, 2003, 3, 125-133.
41. Ozkan A, Fişkin K: Serbest radikaller, karsinogenez ve antioksidan enzimler. Turk J Oncol Hematol, 2004, 1, 2-11.
42. Ozkan A, Fişkin K: Cytotoxicities of low dose epirubicin HCl combining lymphokine activated killer cell against hepatocellular carcinoma cell line hepatoma G2. Turk J Med Sci, 2004, 34, 11-19.
43. Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med, 1967, 70, 158-169.
44. Portera-Cailliau C, Sung CH, Nattans J, Adler R: Apoptotic photoreceptor cell death in mouse models of retinits pigmentosa. Proc Natl Acad Sci USA, 1994, 91, 974-978.
45. Runge D, Köhler C, Kostrubsky VE, Jager D, Lehmann T, Runge DM, May U et al.: Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical reducers in human hepatocytes. Biochem Biophys Res Commun, 2000, 273, 333-341.
46. Siegsmund MJ, Stendler A, Kreukler C, Köhrmann KU, Alken P: Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol, 1997, 31, 365-370.
47. Sinha BK: Free radicals in anticancer drug pharmacology. Chem Biol Interact, 1989, 69, 293-317.
48. Snedocor GW, Cochran WG: Statistical Methods. 6th edn. Ames, Iowa State University Press, USA, 1967.
49. Thomas CE, Morehouse LA, Aust SD: Ferritin and superoxide-dependent lipid peroxidation. J Biol Chem, 1985, 260, 3275-3280.